
“Breaking News: Lecanemab for Early Alzheimer’s Disease Gets the European Union’s Stamp of Approval!”
Breaking News: Eisai and Biogen Provide Update on Regulatory Review for Alzheimer’s Disease Treatment Exciting developments are happening in the world of healthcare as Eisai Co., Ltd. and Biogen Inc. announce an update on the regulatory review of the Marketing Authorization Application for lecanemab as a treatment for early Alzheimer’s disease in the European Union….